Hepatitis B Results Provide Boost To Dynavax's Stock Nov. 30, 2006 By Aaron Lorenzo No Comments Shares in Dynavax Technologies Corp. soared 32 percent Wednesday on positive Phase III data for its hepatitis B vaccine, Heplisav. (BioWorld Today)Read More